Yoshikawa, Toshiaki

Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research

Immunotherapy and Immune ResponsesHepatocellular Carcinoma Treatment and Prognosis

Cited by 302

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology

Hepatocellular Carcinoma Treatment and PrognosisImmunotherapy and Immune Responses

Cited by 178

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma

Tsuchiya, N., Yoshikawa, T., Fujinami, N., Saito, K., Mizuno, S., Sawada, Y., Endo, I., & Nakatsura, T. (2017) · OncoImmunology

Immunotherapy and Immune ResponsesHepatocellular Carcinoma Treatment and Prognosis

Cited by 67